JP3971299B2 - α−１アドレナリン作動性拮抗薬としてのキナゾリン誘導体 - Google Patents

α−１アドレナリン作動性拮抗薬としてのキナゾリン誘導体 Download PDF

Info

Publication number
JP3971299B2
JP3971299B2 JP2002523466A JP2002523466A JP3971299B2 JP 3971299 B2 JP3971299 B2 JP 3971299B2 JP 2002523466 A JP2002523466 A JP 2002523466A JP 2002523466 A JP2002523466 A JP 2002523466A JP 3971299 B2 JP3971299 B2 JP 3971299B2
Authority
JP
Japan
Prior art keywords
methyl
amino
phenyl
dimethoxy
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002523466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507527A5 (enExample
JP2004507527A (ja
Inventor
ベッカー，サイラス・ケフラ
メルビル，クリス・リチャード
プフィスター，ユルグ・ロランド
ツァン，シャオミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004507527A publication Critical patent/JP2004507527A/ja
Publication of JP2004507527A5 publication Critical patent/JP2004507527A5/ja
Application granted granted Critical
Publication of JP3971299B2 publication Critical patent/JP3971299B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002523466A 2000-08-31 2001-08-23 α−１アドレナリン作動性拮抗薬としてのキナゾリン誘導体 Expired - Fee Related JP3971299B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22950300P 2000-08-31 2000-08-31
PCT/EP2001/009749 WO2002018348A2 (en) 2000-08-31 2001-08-23 Quinazoline derivatives as alpha-1 adrenergic antagonists

Publications (3)

Publication Number Publication Date
JP2004507527A JP2004507527A (ja) 2004-03-11
JP2004507527A5 JP2004507527A5 (enExample) 2005-04-07
JP3971299B2 true JP3971299B2 (ja) 2007-09-05

Family

ID=22861517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002523466A Expired - Fee Related JP3971299B2 (ja) 2000-08-31 2001-08-23 α−１アドレナリン作動性拮抗薬としてのキナゾリン誘導体

Country Status (19)

Country Link
US (1) US6559153B2 (enExample)
EP (1) EP1315714B1 (enExample)
JP (1) JP3971299B2 (enExample)
KR (1) KR100602929B1 (enExample)
CN (1) CN1308324C (enExample)
AR (1) AR032475A1 (enExample)
AT (1) ATE309240T1 (enExample)
AU (2) AU2001293788B2 (enExample)
BR (1) BR0113585A (enExample)
CA (1) CA2420177C (enExample)
DE (1) DE60114852T2 (enExample)
ES (1) ES2251512T3 (enExample)
GT (1) GT200100181A (enExample)
MX (1) MXPA03001777A (enExample)
PA (1) PA8527901A1 (enExample)
PE (1) PE20020407A1 (enExample)
UY (1) UY26919A1 (enExample)
WO (1) WO2002018348A2 (enExample)
ZA (1) ZA200301082B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE341552T1 (de) * 2001-08-10 2006-10-15 Neuro Therapeutics Ltd Derivate morphinähnlicher opioidverbindungen
JP2005521728A (ja) * 2002-04-03 2005-07-21 オリオン コーポレーション ＣＮＳ関連疾患のためのα２−アドレナリン受容体アンタゴニストの使用
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EA010852B1 (ru) * 2003-07-24 2008-12-30 Еуро-Селтик С. А. Пиперидиновые соединения и фармацевтические композиции, их содержащие
WO2006021345A2 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b)
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
DE602006010540D1 (de) * 2005-05-04 2009-12-31 Hoffmann La Roche (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008036700A2 (en) * 2006-09-19 2008-03-27 3M Innovative Properties Company Templated metal oxide particles and methods of making
CA2701057C (en) 2007-10-11 2015-03-24 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
ES2761311T3 (es) 2011-04-01 2020-05-19 Astrazeneca Ab Tratamiento terapéutico
SMT201900708T1 (it) 2011-11-30 2020-01-14 Astrazeneca Ab Trattamento di combinazione di un cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CA3055215A1 (en) * 2017-03-12 2018-09-20 Xiaodong Wang Polycyclic amines as opioid receptor modulators
WO2019088095A1 (ja) * 2017-11-02 2019-05-09 国立大学法人九州大学 鎮痛剤及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011698A1 (en) 1995-09-29 1997-04-03 Merck & Co., Inc. ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof

Also Published As

Publication number Publication date
WO2002018348A3 (en) 2002-07-11
ZA200301082B (en) 2004-05-07
GT200100181A (es) 2002-05-23
DE60114852D1 (de) 2005-12-15
US6559153B2 (en) 2003-05-06
CA2420177A1 (en) 2002-03-07
AU9378801A (en) 2002-03-13
WO2002018348A2 (en) 2002-03-07
ES2251512T3 (es) 2006-05-01
UY26919A1 (es) 2002-02-28
CA2420177C (en) 2008-07-08
JP2004507527A (ja) 2004-03-11
EP1315714A2 (en) 2003-06-04
AR032475A1 (es) 2003-11-12
US20020045614A1 (en) 2002-04-18
ATE309240T1 (de) 2005-11-15
PE20020407A1 (es) 2002-05-21
BR0113585A (pt) 2003-07-29
DE60114852T2 (de) 2006-07-27
KR20030022421A (ko) 2003-03-15
KR100602929B1 (ko) 2006-07-20
MXPA03001777A (es) 2003-06-04
CN1545510A (zh) 2004-11-10
EP1315714B1 (en) 2005-11-09
AU2001293788B2 (en) 2007-10-11
PA8527901A1 (es) 2002-07-30
CN1308324C (zh) 2007-04-04

Similar Documents

Publication Publication Date Title
JP3971299B2 (ja) α−１アドレナリン作動性拮抗薬としてのキナゾリン誘導体
JP4031363B2 (ja) α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体
AU2001293788A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
AU2001260310B2 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
EP1112270B1 (en) Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
EP1339694B1 (en) Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
FR2644786A1 (fr) Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP2013534229A (ja) バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体
KR100802856B1 (ko) 아릴아민-치환된 퀴나졸린온 화합물
JP4353803B2 (ja) ムスカリン受容体アンタゴニストとしての４−ピペリジニルアルキルアミン誘導体
WO2000055143A1 (en) Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
JP2009513504A (ja) ５−置換キナゾリノン誘導体
JP4322675B2 (ja) ムスカリン受容体アンタゴニストとしてのアミノテトラリン誘導体
US6355641B1 (en) Oxazolone derivatives and uses thereof
US6417186B1 (en) Substituted-phenyl ketone derivatives as IP antagonists
US6645971B1 (en) Quinazolinone derivatives
JP4454622B2 (ja) アルファ−１アドレナリン作動性アゴニストとしてのメチルインドール及びメチルピロロピリジン
JP2009513521A (ja) プロスタグランジンｉ２アンタゴニストとしてのチオフェニルアミノイミダゾリン類
JP2002503724A (ja) 良性前立腺過形成の治療で用いるに有用な新規な置換ピリジノアリールピペラジン類
JP2004526721A (ja) Ｉｐアンタゴニストとしてのアルコキシカルボニルアミノヘテロアリールカルボン酸誘導体
KR20060008951A (ko) Ｉｐ 길항제로서 이미다졸린-2-일아미노페닐 아마이드
JPWO2003016299A1 (ja) キナゾリノン誘導体

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070607

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees